Company intelligence / Profile preview

Alphaeus

Chanhassen, Minnesota, United Statesalphaeusmfg.com ↗

Ownership: Private
Development stage: Other

Overview

Alpheus Medical’s sonodynamic therapy platform has shown promising early results. In a Phase 1/2 trial for recurrent or refractory high-grade gliomas, median overall survival was doubled and progression-free survival improved threefold compared to historical data. The treatment demonstrated a strong safety profile, selectively targeting cancer cells while sparing healthy tissue. A randomized controlled Phase 2B trial in newly diagnosed GBM is planned for further validation.

Therapeutic areas: Oncology
Modalities: DeviceSmall molecule (oral 5-aminolevulinic acid)
Industry: Biotech

Partnerships

BrightEdge, impact investment arm of American Cancer SocietyBrain Tumor Investment Fund, subsidiary of National Brain Tumor SocietySontag Innovation Fund, subsidiary of The Sontag Foundation

Beyond the preview

Go deeper on Alphaeus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphaeus.

Explore the full profile